埃达拉对骨关节炎的治疗作用:向NRF2信号和线粒体功能
Chao Jiang1,2, Yuhang Gong1,2, Xinyu Wu1,2
1Department of Orthopaedics, Taizhou Hospital Affiliated to Wenzhou Medical University, Taizhou, China.
Journal of orthopaedic translation
|May 8, 2025
概括
埃达拉 (EDA) 通过保护软骨细胞和减少炎症,在治疗骨关节炎 (OA) 中表现有前途. 这种FDA批准的药物激活NRF2通路,为OA提供了潜在的新疗法.
科学领域:
- 生物医学科学 生物医学科学
- 药理学 药理学是指药理学的学科.
- 整形外科 整形外科 整形外科
背景情况:
- 骨关节炎 (OA) 是导致残疾的主要原因,治疗选择有限.
- 氧化应激在OA的发病过程中起着重要作用.
- 埃达拉 (EDA) 是一种自由基清除剂,其在OA中的治疗潜力正在被探索.
研究的目的:
- 研究埃达拉 (EDA) 对骨关节炎 (OA) 的治疗作用.
- 阐明EDA在OA行动的基本机制.
- 评估EDA在OA治疗中重新利用的潜力.
主要方法:
- 实验室内:用t-丁氧化物 (TBHP) 诱导氧化应激;评估EDA对功能障碍,亡,炎症和线粒体功能的影响.
- 在体内:小鼠中介半月体 (DMM) 模型的不稳定,以评估EDA对OA进展的影响.
- 遗传模型:用于确定NRF2在EDA机制中的作用的Nrf2淘汰赛 (-/-) 小鼠.
主要成果:
- 埃达拉 (EDA) 缓解了氧化应激诱导的慢性细胞功能障碍,亡和炎症.
- EDA保留了 mitochondrial 功能和chondrocytes 中的氧化还原平衡.
- 确定NRF2通路的激活是EDA对OA的保护作用的关键机制,在Nrf2小鼠中得到证实.
结论:
- 埃达拉 (EDA) 通过保护色素细胞,显示出显著的潜力来减缓OA的进展.
- EDA的机制涉及激活NRF2通路,稳定线粒体功能,并维持氧化还原稳定.
- 这些发现支持edaravone作为一种治疗骨关节炎的新疗法.
更多相关视频
08:39Experimental Protocol for Detecting Mitochondrial Function in Hepatocytes Exposed to Organochlorine Pesticides
Published on: September 16, 2020
7.9K
08:33Author Spotlight: An Optimized Automated Method for Investigating Retinoic Acid Receptors in Neuronal Mitochondria
Published on: July 28, 2023
513
相关概念视频
01:46Electron Transport Chain: Complex I and II
9.6K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
9.6K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
316
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
316
02:26NF-κB-dependent Signaling Pathway
7.2K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.2K
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
87
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
87